Cell News and Research

RSS

Senators Harkin, Kennedy and Specter honored as champions of health research

The Foundation for the National Institutes of Health, Research!America and the Albert and Mary Lasker Foundation recognized these three senators for their continued support of research for health, their leadership and shared commitment to making it a high national priority, on Tuesday evening August 4th at the Russell Senate Office Building.

6 Aug 2009

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.

6 Aug 2009

Discovery of common trigger in cancer and normal stem cell reproduction

Researchers at Stanford University School of Medicine have discovered, for the first time, a common molecular pathway that is used by both normal stem cells and cancer stem cells when they reproduce themselves.

6 Aug 2009

Thermogenesis expands collaboration with Celling Technologies

ThermoGenesis has announced an expanded collaboration with Celling Technologies, a subsidiary of SpineSmith, LLC, related to the Company's bone marrow products, MXP(TM) MarrowXpress(TM) and Res-Q(TM) 60 BMC. Celling is a leading distributor of orthopedic products, based in Texas.

6 Aug 2009

GE Global Research Biosciences technology celebrated fifth anniversary

From creating a new business in digital pathology to developing next generation diagnostic imaging agents and life sciences tools that are breaking new ground in the detection and treatment of disease, the Biosciences technology organization at GE Global Research today celebrated its fifth anniversary.

6 Aug 2009

Bellicum Pharmaceuticals starts phase I/II trial of novel advanced prostate cancer vaccine

Bellicum Pharmaceuticals, Inc. today announced dosing of the first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer. The disease-specific trial is being conducted under a Bellicum Investigational New Drug application allowed by the FDA in 2008. The company anticipates reporting initial results of the study in 2010.

6 Aug 2009

Genetic profiling of tumors could have 'immediate impact' on treating cancer

New work by MIT cancer biologists shows that the interplay between two key genes that are often defective in tumors determines how cancer cells respond to chemotherapy.

6 Aug 2009

Discovery of cells responsible for bladder cancer spread

Johns Hopkins scientists have tracked down a powerful set of cells in bladder tumors that seem to be primarily responsible for the cancer's growth and spread using a technique that takes advantage of similarities between tumor and organ growth. The findings, reported in the July Stem Cells, could help scientists develop new ways of finding and attacking similar cells in other types of cancer.

6 Aug 2009

Protein unfolding key to understanding blood clot mechanics

Fibrin, the chief ingredient of blood clots, is a remarkably versatile polymer. On one hand, it forms a network of fibers -- a blood clot -- that stems the loss of blood at an injury site while remaining pliable and flexible. On the other hand, fibrin provides a scaffold for thrombi, clots that block blood vessels and cause tissue damage, leading to myocardial infarction, ischemic stroke, and other cardiovascular diseases. How does fibrin manage to be so strong and yet so extensible under the stresses of healing and blood flow?

6 Aug 2009

Reversible cell-specific drug delivery with aptamer-functionalized liposomes

For cancer drug developers, finding an agent that kills tumor cells is only part of the equation. The drug must also spare healthy cells, and - ideally - its effects will be reversible, to cut short any potentially dangerous side effects.

6 Aug 2009

Scientists create stem cells from developing sperm

The promise of stem cell therapy may lie in uncovering how adult cells revert back into a primordial, stem cell state, whose fate is yet to be determined. Now, cell scientists at the Johns Hopkins University School of Medicine have identified key molecular players responsible for this reversion in fruit fly sperm cells.

6 Aug 2009

Discovery of 'tell-tale' viral signature in blood that identifies underlying viral infection

Scientists have identified a genomic "signature" in circulating blood that reveals exposure to common upper respiratory viruses, like the cold or flu, even before symptoms appear.

6 Aug 2009

Pattern of gene expression in blood provides clues to etiology of respiratory infections

Scientists have shown that they can identify and characterize an individual's response to a respiratory viral infection by examining the pattern of gene expression in their blood.

6 Aug 2009

Fast-tracked H1N1 vaccines will not compromise safety, WHO says

Efforts to fast-track the approval of H1N1 (swine) flu vaccines will not compromise the safety or quality controls of vaccine production, the WHO said in a written statement Thursday, the Mail & Guardian reports.

6 Aug 2009

Colon cancer may yield to cellular sugar starvation

Scientists at the Johns Hopkins Kimmel Cancer Center have discovered how two cancer-promoting genes enhance a tumor's capacity to grow and survive under conditions where normal cells die.

6 Aug 2009

Alnylam and Tekmira to collaborate on RNAi therapeutics

Alnylam Pharmaceuticals, Inc. and Tekmira Pharmaceuticals Corporation announced today that they will jointly participate in a new research collaboration focused on the discovery of novel cationic lipids and lipid nanoparticles for the systemic delivery of RNAi therapeutics.

6 Aug 2009

Phytomedical partners with LATITUDE Pharmaceuticals on lead anti cancer compound for glioblastoma

PhytoMedical Technologies, Inc. has announced their partnership with LATITUDE Pharmaceuticals, Inc. to develop an IV Formulation for its lead anti cancer compound for glioblastoma. LATITUDE Pharmaceuticals, Inc. is a widely recognized expert in the area of drug formulations and delivery systems.

6 Aug 2009

New approach targets gut hormone to lower blood sugar levels

A research team led by Dr. Tony Lam at the Toronto General Research Institute and the University of Toronto discovered a novel function of a hormone found in the gut that might potentially lower glucose levels in diabetes.

6 Aug 2009

Unstable proteins can cause premature ageing

The normal ageing process has long been linked to problems with cell respiration, the process through which the cells extract energy from nutrients.

6 Aug 2009

Noninvasive MRI helps diabetes diagnosis and treatment

Noninvasive imaging (MRI) may aid physicians in the early diagnosis, staging and treatment of diabetes, according to a study performed at Massachusetts General Hospital and Harvard Medical School in Boston, MA. This is the first study of its kind to apply noninvasive imaging techniques to diabetes research.

6 Aug 2009